New real-world observational analysis of Uptravi underscores the importance of risk assessment for treating pulmonary arterial hypertension patients -Johnson & Johnson

Findings from an analysis of the first 500 patients enrolled in the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry) found more than three-quarters (76%) of pulmonary arterial hypertension (PAH) patients treated with Uptravi (selexipag)from Johnson & Johnson, either maintained (56%) or reduced (20%) their one-year mortality risk score. The SPHERE results were published in the April issue of the Journal […]